"We are a biotechnology company focused on the clinical development and potential commercialization of our product candidate,
leronlimab (PRO 140), which is being studied for the treatment of Human Immunodeficiency Virus (HIV) infection, nonalcoholic
steatohepatis (NASH), oncology and other immunological indications. Our current business strategy is to seek the removal of the partial and
full clinical holds recently imposed by the FDA in March 2022, evaluate feasibility and timelines for the resubmission of our BLA for
leronlimab as a combination therapy for highly treatment-experienced HIV patients, and to seek to further develop leronlimab for other
HIV-related indications. We also seek to advance our clinical development of leronlimab for various forms of cancer, including metastatic triple negative breast cancer and other solid tumors, as well as to continue to evaluate NASH and Non-Alcoholic Fatty Liver Disease, and
concurrently to explore other potential immunologic indications for leronlimab."

Be nice to include long haulers, this Fall could be a real uptick!